Our data assign a prognostic value to altered SETD3 expression in breast cancer that depends on p53 mutation status and provides proof for a role of SETD3 in the viability, motility, cytoskeletal organization, and invasiveness of triple-negative breast cancer cells. The gene discussed is TP53; the disease is breast cancer.